Stay updated on Efgartigimod Safety & Efficacy in pSS Clinical Trial

Sign up to get notified when there's something new on the Efgartigimod Safety & Efficacy in pSS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efgartigimod Safety & Efficacy in pSS Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Posted results and updated outcome measures are now on the page for NCT05817669, including primary and secondary outcomes and safety data, with the Results First Posted date of 2025-07-18.
    Difference
    0.4%
    Check dated 2025-11-03T20:50:52.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    39 days ago
    Change Detected
    Summary
    - Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. The page now communicates operating status details and a newer software version.
    Difference
    3%
    Check dated 2025-10-06T05:19:27.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    Added version update to v3.1.0 and removed several topic headings (MedlinePlus drug safety topics and an older v3.0.2), indicating a reorganization and upgrade rather than new substantive content.
    Difference
    0.5%
    Check dated 2025-09-29T02:59:42.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2 and the Back to Top element was removed.
    Difference
    0.2%
    Check dated 2025-09-14T19:04:09.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.
    Difference
    0.2%
    Check dated 2025-09-07T15:07:18.000Z thumbnail image
  8. Check
    74 days ago
    Change Detected
    Summary
    The web page has been updated to include new facility names and locations related to drug safety and information, specifically highlighting the availability of Efgartigimod Alfa in various cities across Belgium and Poland, while removing previous references to Sjögren syndrome and related topics.
    Difference
    5%
    Check dated 2025-08-31T11:47:52.000Z thumbnail image

Stay in the know with updates to Efgartigimod Safety & Efficacy in pSS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efgartigimod Safety & Efficacy in pSS Clinical Trial page.